Rugo, H.S., Barry, W.T., Moreno-Aspitia, A., Lyss, A.P., Cirrincione, C., Leung, E., Mayer, E.L., Naughton, M., Toppmeyer, D., Carey, L.A., Perez, E.A., Hudis, C. and Winer, E.P. (2015) Randomized Phase III Trial of Paclitaxel Once per Week Compared with Nanoparticle Albumin-Bound Nab-Paclitaxel Once per Week or Ixabepilone with Bevacizumab as First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 33, 2361-2369.
https://doi.org/10.1200/JCO.2014.59.5298

has been cited by the following article:

• TITLE: Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient

  AUTHORS: Maria Rosaria Valerio, Chiara Ancona, Antonella Marchese, Vittorio Gebbia

  KEYWORDS: Nab-Paclitaxel, Trastuzumab, HER-2, Metastasis, Breast Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.11, November 16, 2017

  ABSTRACT: Background: Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However, the role of late-line treatment in heavily pretreated patients is still largely unclear. In the last decade, nab-paclitaxel has shown significant activity and good toxicity profile in metastatic breast cancer. Case Presentation: We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral capecitabine and lapatinib. Clinical and radiological staging showed progression at bone, skin and soft-tissue. The patient received weekly nab-paclitaxel plus trastuzumab. Massive objective response was clinically and PET documented which lasted 8 months. Tolerance to treatment was fairly good as well as cardiac safety. Conclusion: To the best of our knowledge, this is the first reported case of efficacy of nab-paclitaxel in combination with trastuzumab as fifth-line of treatment in a patient with metastatic HER-2 positive breast cancer.